Lepu Bio-B (02157) rose more than 13% at the end of the session. As of press release, it was up 9.09% to HK$3.6, with a turnover of HK$10.4921 million.
The Zhitong Finance App learned that Lepu Bio-B (02157) rose more than 13% at the end of the session. As of press release, it had risen 9.09% to HK$3.6, with a turnover of HK$10.4921 million.
According to the news, Lepu Biotech recently announced that its drug candidate MRG004A (a novel specific antibody drug conjugate targeting tissue factors) has been granted Fast Track Qualification (FTD) by the US Food and Drug Administration (FDA) to treat pancreatic cancer.
According to reports, MRG004A is a novel specific antibody drug conjugate targeting tissue factors. Phase I/II clinical studies are currently being conducted in the US and China. The company has observed anti-tumor activity signals for pancreatic cancer, triple-negative breast cancer, and cervical cancer.